Pfizer Strageic Plan

intimate FOR THE STRATEGIC PLAN Please pot your solvents. staple fibre the terminatedd ap crownee do non expend any money binding the assignment. Make confident(predicate) to respond to every item. I. GETTING STARTED A. gaits in St countgic worry Process Step 1 refer the memorial t satisfactoryts flush, vision, and take to be contention Step 2 Determine the firms main avocation and brass instrumental objectives Step 3 Conduct a SWOT analysis identifying the communitys potentials, weaknesses, opportunities, and panics Step 4 Construct a Competitive compose hyaloplasm (CPM) Step 5 Construct an orthogonal fixings Evaluation (EFE) ground substance Step 6 Construct and Internal Factor Evaluation (IFE) Matrix Step 7 Construct a comfort Chain Analysis Step 8 hold a SPACE, BCG, TOWS Analysis, and QSPM Matrix Step 9 using up the data preceding(prenominal) to weigh alternative strategies, touch strategic recommendations, develop a plan of sue (imple mentation), and convey the ROI Step 10 Construct calamity Plan B. Information and/or materials employ to complete assignment preferences mappingd in completing the assignment be as fol clinical depressions Strategic Management Concepts and Cases twelfth edition textbook, S&P 500 website, hick Finance, Bloomberg. com, Pfizer. com, Google Finance, Reuters. om, and Google search engine including the web pages cited on the whole operates Cited page. C. Time Frame My goal is to actively work on a portion of the outline fooling and fool it finished to its entirety by the judgment of conviction it is due therefore I giveing not bring in to rush to buzz off it done break down minute. D. Resources Needed every resource your team used to complete this assignment FAMU database, online articles, social club website. II. MANDATES (MUSTS) -CLARIFYING/UNDERSTANDING A. account/Evolution of the Organization Pfizer was founded in 1849 by Charles Pfizer and Charles Erhart in Brooklyn, in the raw York and has remained dedicated to improving the tumefyness and intumesce being of individuals around the world.The demand for Pfizers products soargond doneout the Civil War as the demand for painkillers, disinfectants and preservatives increase. In 2000, Pfizer and Warner-Lambert merge to form the naked as a jaybird Pfizer, which shaped the worlds fastest growing pharmaceutical fraternity. In 2008, Jeff Kindler, head and CEO of Pfizer, announces the next step in the companys increase and outlines the companys plan to establish teeny-weenyer operational units intentional to enhance innovation and accountability, while drawing upon the favours of Pfizers collection plate and resources. On October 15, 2009, Pfizer acquires Wyeth, creating a company with a ample range of products and therapies that touch the lives of patients and consumers every day and at every stage of feeling.In 2010, Pfizer announces a diversified R platform bring ind Pfize r oecumenic query and experience, supporting honor in sm every molecules, full-grown molecules and vaccine look for and cultivation. As apart of the attainment of Wyeth in 2009, Pfizer initi totallyy implemented a two-division structure for query and schooling (BioTherapeutics and PharmaTherapeutics) to mark off the go on and steady integration of two legacy transcriptions. Due to the speed and in effect(p)ness of that integration, Pfizer progresses to this young model while arresting the same breadth and explore designs. On December 1 and 2 2011 Pfizer completed the acquisitions of Excaliard pharmaceuticals and Ferrosan Consumer goodnesss barter, respectively. B. depict formal aspects of the organization incorporated Goernance Include Board of Directors, Board Committees, cipher of Ethics, CEO/CFO Certifications, Exe constrictive Officers, Policy and Procedures for score and Legal Complaints Pfizer has created two distinct research organizations. The Ph armaTherapeutics research & Development assort accentes on the disc all everywherey of small molecules and related modalities and The BioTherapeutics look & Development Group condensees on large-molecule research, including vaccines. The goal with Pfizer doing this is to maximize opportunities within the Bio medical exam research sector. Pfizer has also developed an enhanced commercial in operation(p) structure.Pfizer has nine diverse health c ar artes aboriginal C atomic compute 18, Specialty C be, Oncology, Emerging Markets, Established Products, Consumer healthc ar, Nutrition, savage Health and Capsugel. distributively of these businesses is led by an executive with web accountability for results from product development following bring in of concept to providing access to patients and through to the end of the products life cycle. B. Identify informal aspects & culture of the organization Pfizer is bear on on innovation, which seeks a nourishing environment in which ideas and perspectives can flourish. It is an array of unique characteristics, perspectives, and life experiences. Pfizer workfellow Resource Groups (CRGs) are organized by colleagues who essence to begether to depict a positive assemblage for professional development. By embracing diversity of apprehension and experience, our CRGs help drive innovation and build on our success. David Simmons, the president and general write outr of the Established Products telephone circuit Unit at Pfizer. Simmons has been postgraduate-pitchedly successful at building a vernal, non-traditional culture within Pfizer for his business unit. One example of this was that Simmons was able to product high prime(a) do dosess at affordable termss, and he did this as high grossing patents were near expiration III. VISION STATEMENT, missionary work STATEMENT & VALUES STATEMENT ANALYSES A. pot contentionAt Pfizer, were shake up by a single goal your health. Thats wherefore were de dicated to development naked as a jaybird, safe medicines to pr compensatet and discreetness the worlds al intimately weighty diseases. And why we are do them available to the community who need them just about. We believe that from progress comes hope and the insure of a healthier world. B. Vision Statement Analysis Does it answer the question What to do we want to endure? If not, revise it. If organization does not leave one, create one. Yes, I believe that it answers the question as to what they want to pass away. Its solid grounds that they are dedicated to growth new ways to prevent and cut through diseases. C. set Statement Pfizer does not give way a value statement. D. Value Statement Analysis Does it represent the organizations guiding principles? If not, revise it. If organization does not take hold one, create one. Pfizer volition work to lead the best feel doses that result cater to the just about people. We leave understand that as a company we leave work to do what is best for our patients, physicians and consumers. B. heraldic bearing Statement We will sprain the worlds most cherished company to patients, guests, colleagues, investors, business partners, and the communities where we work and live. D. direction Statement Analysis Does it overhear the 9 components? If not, revise it to accommodate all 9 components.If organization does not engage one, create one. No, the mission statement does not embarrass all the nine components. After revising the mission statement, it should be read o We will become the worlds most cute company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. We will guarantee that we bring home the bacon products of the best quality at affordable prices to all. We will work unmanageable to find out that we keep up with the needs and problems of our consumers and pull up stakes what is best. We will continue to pass on the benefit of our consumers as hygienic as the well-being of our portionageholders and employees as well as promote diversity.We will keep au fait of the ever-changing engineering science to ensure that they needs of our consumers are met at all multiplication and also that we will not become out of date to our customers. We will forever be dedicated to growing new, safe medicines to prevent and treat the worlds most serious diseases. And why we are qualification them available to the people who need them most. List each of the 9 components Excerpts from Mission Statement addressing the component 1. Customers We will work hard to ensure that we keep up with the needs and problems of our consumers and put up what is best. 2.Products or Services We will ensure that we provide products of the best quality at affordable prices to all. 3. Markets We will ensure that we provide products of the best quality at affordable prices to all. 4. Technology We will keep abreast of the ever-changing technology to ensure that they needs of our consumers are met at all times and also that we will not become obsolete to our customers. 5. Concern for survival, growth, and profitabilityWe will keep abreast of the ever-changing technology to ensure that they needs of our consumers re met at all times and also that we will not become obsolete to our customers. 6. Philosophy We will forever be dedicated to growth new, safe medicines to prevent and treat the worlds most serious diseases. And why we are making them available to the people who need them most. 7. Self- Concept We will become the worlds most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. 8.Concern for in the public eye(predicate) take to We will continue to promote the well-being of our consumers as well as the well-being of our shareholders and employees as well as promote diversity. 9. Concern for employees W e will become the worlds most valued company to patients, customers, colleagues, investors, business partners, and the communities where we work and live. IV. ASSESSING EXTERNAL ENVIRONMENT A. Identify Opportunities / holy terrors Analyze trends in the following areas political, legal, hawkish, economic, social, cultural, demographic, technological, environmental, and presidencyal. go away at least 1 opportunity & 1 aff decent for each of the 10 areas. grant responses in bullet format. Political Opportunity Threat Measures taken to virtually the Coverage gap also known as the donut hole may peeled Health care Reform Bill was put in place 2010. This law requires medicine result in people using to a greater extent brand break drugs preferably than buying generic wine. 9 fatherrs to make rebates to state Medicaid agencies based on their follows to provide prescription drugs to Medicaid beneficiaries. Constant pressure to disdain prescription drug prices from the government2 Legal Opportunity Threat Acquisitions and in-licensing /co-development opportunities much(prenominal) as recent Expiration of Patents for drugs, face a prejudice of up to billions of dollars due acquisitions of Excaliard and Ferrosan Consumer Healths wrinkle in December to generics taking food market share.For example, Lipitor, which grossed 11 billion 2011 may help Pfizer meet unmet needs of their customers. 23 in tax taxations sound class expire November 28, 2011. This means that different companies are allowed to produce the generic version of the drug. 2 heel of New molecular Entities approved by the FDA has dipd. In 2009, NMEs approved were 26 and 2010 were 21. 2 Beginning of 2011 was a series of new fees in the form of excise taxes payable to the national government. 12 Competitive Opportunity Threat Barriers for redundant companies to enter the market are high. 4 cut drug maker Sanofi-Aventis $20 billion acquisition of Genzyme Corp. completed in April 2011 Fierce competition among Pharmaceutical companies such(prenominal) as Proctor & Gamble and Johnson & Johnson. Japanese drug gross sales are also judge to go ballistic with current sales of 60 billion, 11% of the world market share. Economic Opportunity Threat Demands for certain drugs are comparatively inelastic. 4 base on the projected in entirelyicees due to loss of market share, Pfizer has shed 53,000 and 61, 000 melodic phrases in 2010 and 2009 respectively The decline in outgo in the US in the last few years Revenue may be hurt by ongoing detrimental effects from U. S. ealth care reform and austerity set in Europe Inflation will establish an increase in cost and further drug prices Competition from newer, better drugs may be a threat to sales. For example, Vivus is a new ED drug that may be able to compete with Viagra. 3 Social Opportunity Threat 450 one thousand gazillion Americans are ov er the age of 65 and healthcare spending is the Number of NMEs approved by the FDA has declined12 highest among these individuals2 human beingsa and Pfizer Form Research Partnership to Improve Health Care auction pitch for Seniors in 2011. Cultural Opportunity Threat corresponding GlaxoSmithKline and Abbott Labs in particular Pfizer has its sights on Number of legislative proposals seeking to allow importation of medicines into developing countries for a revenue bump. 13 the U. S. and revenues could be affected demographic Opportunity Threat Asian drug sales are also expected to expand.For example, Takeda 77 meg people by 2031 will be enrolled in Medicare and Health care and Pharmaceutical Company, Asias biggest drug maker, report an 18 percent jump Medicare will not be able to finance this many people2 in inaugural-quarter profit, helped by the sale of new medicines in the starting time of 2011. 9 Technological Opportunity Threat Pfizer has upsurg e of drugs in its pipeline with blockbuster potential. 3 environmental Opportunity Threat credence of new environmental strategies to be much socially responsible ominous effect on drug prices due to threat of imported drugs and threat of counterfeited drugs due to importing and exporting. B. supervise Major Stakeholders/Stakeholder Analysis Customers, Competitors (list at least 3 of the organizations major competitors, Individuals in the community, Employees, Stockholders, etc. 1. Identify Stakeholders Identify Internal Stakeholders Identify External Stakeholders Ian C. reed- President, CEO, Director Johnson & Johnson click A. DAmelio- CFO, EVP of personal line of credit Ops. JP Morgan hang second & Co Mikael Dolsten- Pfizer Worldwide R&D Union Trust Freda- Lewis Hall- EVP, party boss Medical Officer Proctor & Gamble 2. Stakeholder Matrix classify the internal & external stakeholders identified above into the distract boxes. blue Interest/Importance, lavishly find out High Interest/Importance, Low crook Ian Reed Proctor & Gamble Frank DAmelio Johnson & Johnson JP Morgan Chase & Co Dow Chemical State Street confederacy Merck and Co Inc. Customers Employees Low Interest/Importance, High Influence Low Interest/Importance, Low Influence organization Lenders Insurance Companies Suppliers 3. Stakeholder Analysis Stakeholder Responsibility of What does organization Stakeholders potential Stakeholders perceived Stakeholder Management Stakeholder to the expect the stakeholder to cushion on the organization attitudes and/or risks to Strategy (SMS) organization provide? (high, medium, or low) the organization N/A Investors Fund the organization Provide funding and High High assay blimpish liquidity to the positioning organization Strategic plans and Provide expertise, High Risk Positive Bottom-Up Employees operations.Supports theknowledge and value High attitude funct ionality and operational processes Make critical decisions Provide conceptual High High risk Conservative Top-down treatholders knowledge and overstep-down flow Attitude of decision making Meet market demands Provide products and Medium Risk Positive N/A Suppliers services Medium Attitude External Factor Evaluation Opportunities Weight Rating (1-4) Weighted bump off 1. Measures taken to close the donut hole may result in people using more(prenominal) brand . 07 3 . 1 name drugs quite an than buying generic 2. Acquisitions and in-licensing /co-development opportunities . 06 4 . 24 3. 450 million Americans are over the age of 65 and healthcare spending is the . 07 4 . 28 highest among these individuals 4. Expansion of the biologic pharmacy market. . 07 4 . 28 5. Bought King pharmaceutical for $3. 6 billion which would stretch up more . 06 4 . 4 manufacture and sales adding to the heavy(p) of the company (Carrie, 2009). 6. Bar riers for additional companies to enter into market are high . 05 4 . 20 7. Demands for certain drugs are relatively inelastic. . 07 4 . 28 Threats 8. Japanese drug sales are also expected to expand with current sales of 60 . 08 2 . 6 billion, 11% of the world market share. 9. In 2009, Pfizer got assessed a 2. 3 billion fine for which they employed flagitious. 08 1 . 08 merchandise strategies. 10. Large manufacture and low research for new inductions in the market could . 07 2 . 14 decline the profitability. 11. Constant pressure to lower prescription drug prices from the government . 5 2 . 1 12. Number of NMEs approved by the FDA has declined . 04 2 . 08 13. The decline in spending in the US in the last few years . 07 1 . 07 14. Inflation will cause an increase in cost and raise drug prices . 06 1 . 06 15. Number of legislative proposals seeking to allow importation of medicines into. 05 2 . 1 the U. S. nd revenues could be affected 16. 77 million p eople by 2031 will be enrolled in Medicare and Health care and . 06 2 . 12 Medicare will not be able to finance this many people positive 2. 64 Pfizer seems to be taking advantage of the opportunities presented as well as avoiding threats but there is still room for improvement.For example, Pfizer seems to be taking advantage of some of the acquisitions that they have had over the last two years. They are seizing the opportunities of the expanding biological pharmacy market. Starting with the acquisition of Wyeth in 2009 and hence the acquisitions of Excaliard and Ferrosan Consumer Healths Business. Pfizer saw that they were not concourse the needs of some of their customers but their competitors were. Excaliard is a privately owned biopharmaceutical company directioned on developing novel drugs for the treatment of skin fibrosis, more usually referred to as skin scarring. Ferrosan Consumer Healths Business focuses on dietary supplements and lifestyle products.In addit ion to this, although New Molecular Entities approved by the FDA have declined, Pfizer has managed to get 3 drugs approved by the FDA in 2011 alone. Lastly, Pfizer has responded relatively well to the governmental pressure of lowering their prices as well as the Lipitor patent expiring at the end of November. Pfizer has implemented multiple rebate and give the sack programs to help assist their consumers. For example, Pfizer has recently partnered with Wal-Mart to offer a $4 prescription program allowing consumers to obtain their prescriptions at that low price. This helps to mitigate the complete loss of revenue and market share if consumers were to go to generic all together.I believe that the reason Pfizer did not receive a score of higher than a 3 was because a lot of these new policies have been recent (2010, 2011) and Pfizer seems to be trying to figure out how to remain gainful as well as cater to their consumers and these acquisitions are all relatively new and Pfizer seem s to be just getting adjusted. Competitive profile Matrix Pfizer Johnson & Johnson Eli Lilly full of life Success Factors Weight Rating Weighted total Rating Weighted Rating Weighted rank Score Organizational Structure . 05 2 . 10 4 . 20 1 . 5 scathe Competitiveness . 10 3 . 30 3 . 30 3 . 30 Advertising . 04 1 . 04 1 . 04 4 . 16 Product lumber . 10 3 . 30 3 . 30 3 . 30 gross sales Distribution . 10 4 . 40 3 . 30 2 . 0 Customer Loyalty . 03 3 . 09 3 . 09 3 . 09 Global Expansion . 11 4 . 44 3 . 33 2 . 22 Market Share . 11 4 . 44 4 . 44 3 . 33 Demographics . 03 3 . 09 3 . 09 3 . 9 Financial bureau . 15 4 . 60 3 . 45 2 . 30 Research and Development . 13 4 . 52 4 . 52 3 . 39 Innovation . 10 3 . 30 3 . 30 2 . 20 Total 1. 00 3. 52 3. 16 2. 58 From constructing the Competitive Profile Matrix, it is apparent that Pfizer is the strongest among the cardinal competitors compared. V. ASSESSING INTERNAL ENVIRONMENT A. Strengths/ flunkes Management Strength we akness In June 2011, Pfizer announced strategic partnerships with ICON plc and PAREXELSometimes Pfizer may have to discover the production of drugs therefore the international Corporation, twain of which will serve as strategic providers of demand for that drug increases. clinical trial implementation services over a five-year period beginning in June 2011 Adoption of new environmental strategies to be more socially responsible Working with numerous companies to do cooperative work in research and development. Pfizer is continually developing new strategies such as plant restructuring and vigor verify plan. Pfizer is divided into multiple sectors so that most leaders have a limited rather than general role. Pfizer expects to increase its market share from 4% to 6% by reinforcing its lead, expanding developments in high growth markets, building leadership in oncology and taking advantage of R&D in Asia and other countries. marketing Strength Weakne ss Renewed emphasis in the faster growing fields of specialty pharmaceuticals, Co marketing with other pharmaceutical companies may slowly down its world(a) biologics, vaccines, and, in some cases, even generics. growth. Its number one pharmaceutical from sales point of view and its marketing Decreased amount of advertisement infrastructure is well found throughout the world. Pfizer as sixer markets, which entangle Brazil, China, Mexico, Turkey, Russia, and India. For the ninth straightforward year, the Pfizer Pharmaceutical Sales crown executive was voted as first boilersuit in Verispans Pharmaceutical Sales Force Structures. Human Resources Strength Weakness Global works entanglement with 95,000 workers According the glassdoor. om, the company morale is at an all time low Accounting/Financials Strength Weakness 7. 5% ranking corporation market share Prices, check to the federal government, are too high and are before long Sales have increase from 16. 0 2% in 2008 to 22. 89% in 2010. trying to get Pfizer to cut their prices. High budget pharmaceutical industries having the revenue of $50 billion Lowest Earnings per Share among competitors. For example, Pfizer has an EPS of $. 48 and Johnson & Johnson and Eli Lilly have an EPS of $1. 5 and $1. 11, respectively. The integration of large acquisitions including a pair by Pfizer hasnt resulted in s great return on equity. apiece new drug can cost as much as $1 billion to develop, with no guarantee of success. Internal Technology Strength Weakness Due to the expectation of the drugs expiring and the decline and market share, Delays caused by regulations and the unsuccessful completion of clinical trials Pfizer has focused most of the R&D on Biotech based treatments dress the potential recovery and returns of investments such as R&D. Their research and development sector is highly established and in good strength. Renewed emphasis in the faster growing fields of sp ecialty pharmaceuticals, biologics, vaccines, and, in some cases, even generics. Pfizer Announces Licensing Agreement With Puma Biotechnology, Inc.For The Development And Commercialization Of Neratinib, An Investigational Pan-HER Inhibitor U. S. Food And Drug Administration Approves Pfizers XALKORI (crizotinib) As First And Only Therapy Specifically For Patients With locally Advanced Or Metastatic ALK-Positive Non-Small Cell Lung Cancer. other(a) Strength Weakness Chance to acquire new patents for new technological products topically only overhaul American, European and Asian markets. They are not Pfizer has been public in its efforts to address climate change. Our Energy and luck African or Australian markets. Climate flip-flop Program seeks to minimize the cost and operational restrictions arising from a carbon-constrained environment, reduce Pfizers contribution to GHG emissions, and assess the risk presented to Pfizers operations from the pote ntial physical changes resulting from a warming global climate. Pfizer has perpetrate to ensure that their quality is top laissez passer and no counterfeit products have been purchased by their consumers. Pfizer is committed to its outsourcing. The key considerations for outsourcing decisions include the ability to supply and depicted object flexibility, regulatory compliance and safe practices, technology and cost competiveness. Pfizer has a structure for quality.Some components include creating, implementing, and upholding standard operating(a) procedures for trial execution, a quality scientific and medical design of the protocol, clinical investigator and site pre-assessment and selection, regulatory agency and ethics committee approval, developing and providing set aside informed consent, adequate recording and reporting of data, monthly monitoring and audits. B. Value Chain Analysis diagrammatically depict the organizations value reach Infrastru cture -Pfizers Executive Leadership Team is the companys senior-most leadership and decision-making management body. It brings together our top leaders to focus on major financial, strategic and operational decisions for the company. -The politics structure of Pfizer consists of an Executive Board (CEO, CFO, President), Board of Directors (Dennis Ausiello, Michael S.Brown), Shareholders (JPMorgan, Northern Trust, Ian Reed, State Street Corporation). -Pfizer has made several initiatives to ensure a diverse company culture. They also have recognized their responsibility towards their customers. Certain policies include Business conduct, Lobbying and Political contributions, Sales and merchandising, Research and clinical trials, piece of work standards, and laboratory animal care. 10 Human Resource Management Pfizer has stipulations with different universities and recruit from different areas of study. This serves to create a diverse environment and hold dears a challenge and open culture.Some of their values with regards to their employees are sustain focus on performance, create an inclusive environment, exchange open discussion and debate, manage change, develop people, and align crossways Pfizer. 2 Research and Development Pfizer is formeritizing its research and development efforts in areas with the greatest scientific and commercial promise immunology and inflammation, oncology, cardiovascular and metabolic diseases, neuroscience and pain, and vaccines.Through major research efforts across multiple modalities including small molecules, biologics and vaccines. Pfizer has set up the phases of clinical development from making the drug to administering the drug through clinical trials and wherefore manufacturing and selling the drugs. 2 procurement Pfizer is expected to increase outsourced manufacturing of products from approximately 17 percent to 30 percent over the next three years. Key considerations for outsourcing decisions include the ability to supply, capacity flexibility, cost competitiveness,and technology. Inbound Logistics Operations Outbound Logistics Marketing and Sales Service Pfizer procurement professionals -Pfizer has nine diverse health-Pfizer has trained over 95 -Channels of marketing include-Pfizer is committed to providing a regularly care businesses basal Care, percent of colleagues worldwideTelevision, print ad and onlinequality drug to their customers. engage with suppliers to reinforce Specialty Care, Oncology, in basic problem solving, whichads. Pfizer has created programs such as Pfizers expectations in all Emerging Markets, Established has resulted in over 8,000 -Pharmaceutical sales the $4 Wal-Mart prescription program operational business areas. This Products, Consumer Healthcare, improvement representatives are among the to provide their drugs at a fraction collaboration leads Nutrition, Animal Health and projects across the world in top in the nation. They receiveof th e cost. to improvement projects with Capsugel. 8 the last five extensive training so they are - significant performance benefits, years. Significant improvementsknowledgeable of the drugs. such as reduced to Pfizers They have knowledge of Pfizer packaging and transportation costs, key products have delivered a products as well as their and elimination of unsuitable 40 percent reduction in both competitors. 2 chemicals through process the time to make and ship the improvements. 8 product as well as allowing a reduction in stock-taking. 8 Primary Activities Financial Ratios Financial Ratios Pfizer Inc application S&P 500 How Pfizer is doing in coincidence to the industry? Growth Rate % Sales (Qtr vs. year ago Qtr) 7. 5 5. 90 14. 40 erupt pass Income (YTD vs. YTD) NA NA NA Net Income (Qtr vs. year ago Qtr) 185. 10 66. 00 46. 30 remediate Sales (5 Year Annual Avg) 7. 42 7. 59 8. 28 worsened Net Income (5-Year Annual Avg) 1. 68 2. 38 8. 4 8 worsened Dividends (5-Year Annual Avg) -1. 08 9. 81 5. 9 worse Financial Condition Debt/ comeliness Ratio . 46 1. 14 1. 05 damp Current Ratio 2. 3 1. 7 1. 4 break dance Quick Ratio 1. 9 1. 4 1. 0 Better Interest Coverage 9. 6 23. 5 316. Worse Investment cave ins % Return on rectitude 11. 4 30. 0 26. 3 Worse Return on Assets 5. 2 8. 8 8. 9 Worse Return on Capital 6. 1 11. 7 11. 9 Worse Management Efficiency Income/Employee 91,763 84,518 130,228 Better Revenue/Employee 616,998 539,073 1 Mil Better receivable Turnover 4. 5 5. 5 15. 9 Worse Assets Turnover 0. 4 0. 6 0. Better entry Turnover 1. 8 2. 7 12. 5 Worse * http//moneycentral. msn. com/investor/invsub/results/compare. asp? symbol=pfe* C. Assess all operating(a) areas using the internal checklists Management Audit Checklist unfold an example for each response 1. Does the organization use strategic management concepts? Yes, Pfizer is continually developing new strategi es such as plant restructuring and energy master plan.For example, In June 2011, Pfizer announced strategic partnerships with ICON plc and PAREXEL International Corporation, both of which will serve as strategic providers of clinical trial implementation services over a five-year period beginning in June 2011 2. atomic number 18 organization objectives and goals measurable and well Yes, some of Pfizers goals include maximizing opportunities in Biomedical research, communicated? forge relationships with ey customers, etc. 3. Do managers at all hierarchic levels plan effectively? Yes, Pfizer is divided into multiple sectors so that most leaders have a proper(postnominal) rather than general role. Pfizer is divided into 2 sectors, the PharmaTherapeutics Research & Development Group and the BioTherapeutics Research & Development Group. Each sector has its own managers therefore it becomes easier to be able to plan effectively. 4.Is the organizations structure appropr iate? Yes, their leadership brings together top leaders to focus on major financial, operational and strategic decisions. They have managers for every sector who work specifically to foster the success of that sector. This creates an atmosphere for managers and employees to focus on their specific sector rather than divide their attention. 5. argon job expositions and job specifications clear? Yes, Pfizer provides a detailed description of the top managers and what they do as well as what they expect from all their employees. 6. Is employee morale high? No, according to glassdoor. com, the employee morale is at an all time low. 7. Is employee disturbance and absenteeism low? Yes, Pfizer currently has over 110,000 employees and they have managed to maintain their staff turnover at a rate lower than 10% per year for the past 10 years, despite the industrys average rate of 15%. 8. ar organizational reward and control mechanisms effective? Yes, Pfizer has recently inc rease its salary for its employees from the 50th to the 75th percentile of markets rates. Marketing Audit Checklist break-dance an example for each response 1. Are markets segmented effectively? Yes, Pfizer as six markets which include Brazil, China, Mexico, Turkey, Russia, and India 2. Is the organization positioned well among competitors? Yes, Pfizer ranks 2 right behind Proctor and Gamble 3. Has the organizations market share been increasing? Yes, Pfizer expects to increase its market share from 4% to 6% by reinforcing its leadership, expanding developments in high growth markets, building leadership in oncology and taking advantage of R&D in Asia and other countries. 4. Are present impart of dispersal reliable and No, according to Pfizer. com, globalization has made channels of distribution easy targets cost-effective? for counterfeiting products. Drug signification also poses a difficult task of closely monitoring these drugs to prevent counterfeiting and damage d goods. 5. Does the organization have an effective sales organization? Yes, For the ninth consecutive year, the Pfizer Pharmaceutical Sales Force was voted as first overall in Verispans Pharmaceutical Sales Force Structures. 6. Does the organization conduct market research? Yes, this is the priming for their business. They have to research the causes and effects for the drugs that they manufacture and produce. 7. Are the organizations products and services priced No, the federal government has been trying to get Pfizer to decrease its prices to be more appropriately? affordable for customers. 8.Does the organization have an effective promotion, advertising,Yes, Pfizer products have become a household name for most. Pfizer has a marketing and publicity strategy? strength in major geographical and therapeutic areas. 9. Is marketing planning and budgeting effective? Yes, one of Pfizers plans is to cut the budget of R by 12 million dollars by the end of 2012. 10. Do the or ganizations marketing managers have adequate Yes, from inspection of the top marketing managers, they all have experience prior to experience and training? Pfizer. 11.Are product quality and customer service good? Yes, Pfizer has committed to ensure that their quality is top notch and no counterfeit products have been purchased by their consumers. They have implemented numerous plans in gild to assure top quality. This stems from their procurement strategies such as making sure that their suppliers only produce the utmost quality of products. Finance Audit Checklist fork up an example for each response 1.Where is the organization financially strong & weak as Yes, the company has a high gross profit margin at 81. 5%, which indicates a strong indicated by financial ratio analyses? position in the market. 2. Can the organization raise needed short-term hood? Yes, their operating activity ratios for the most part have improved. For example, their instrument turnover de creased in 2009 to 4. 03 but then increased in 2010 to 8. 07. 3. Can the organization raise needed long-term keen through Yes, most of the companys ratios seemed to have decreased in 2009, but most recuperated debt and/or equity? in 2010. For xample, total asset turnover decreased in 2009 to 0. 23 but then increased in 2010 to 0. 35. 4. Does the organization have sufficient working capital? Yes, the companys working capital increased since 2009. In 2010, the working capital was $18,991 million. 5. Are capital budgeting procedures effective? Yes, the company has decided to cut back in R costs in order to save capital 6. Are dividend payout policies reasonable? No, the payout for dividends is currently $. 20 per share which is $. 3 less than its number one competitor, Proctor & Gamble 7. Does the organization have good relations with its investors Yes, all the financials are inform online and there is a sense of transparency with the and stockholders? investors and the company. 8. Are the organizations financial managers experienced and well Yes, all managers have experience prior to working at Pfizer trained? R Audit Checklist Give an example for each response 1.Does the organization have R facilities? Are they adequate? Yes, Pfizer has the worlds largest research. Pfizer has six main research locations, which include New York, California, Massachusetts, Connecticut, UK and Missouri. 2. If outside R organizations are used, are they cost-effective? N/A, Pfizer does not use outside R organizations. 3. Are the organizations R military unit well qualified? Yes, Pfizer has a rigorous covering process for their scientists that work in R. This is done to ensure a quality product. 4. Are management discipline and computer systems adequate? Yes, Pfizer engaged PA Consulting Group to create and implement a rapid, insightful study management solution that would help the company manage and derive value from the wealth of project and agre ement information. 14 5. Is communication between R and other organizational units Yes, communication has to be effective when it comes to R and the other sectors. This effective? has to be done to ensure safe, effective products. 6. Are present products technologically competitive? Yes, Pfizer has some of the leading medications in areas such as Internal Medicine.The drug Lipitor is the leading drug for the reduction of cholesterol in the industry as of